Chemokine receptor - Directed imaging and therapy

Area of Science:

• Oncology
• Nuclear Medicine
• Immunology

Background:

• The CXCR4/CXCL12 axis is vital for cell migration, stem cell homing, angiogenesis, and proliferation.
• Dysregulation of CXCR4/CXCL12 is implicated in cancer metastasis and immune cell trafficking.
• CXCR4 antagonists like Plerixafor are clinically used for stem cell mobilization.

Purpose of the Study:

• To review current positron emission tomography (PET) imaging protocols for CXCR4 expression.
• To highlight the theranostic potential of beta-emitter labeled CXCR4 antagonists.
• To discuss the role of CXCR4 imaging in understanding cancer metastasis and immune responses.

Main Methods:

• Review of preclinical and clinical imaging studies using radiolabeled CXCR4 antagonists (e.g., [68Ga]Pentixafor for PET).
• Analysis of therapeutic applications of beta-emitter labeled CXCR4 antagonists (e.g., [177Lu]/[90Y]Pentixather).
• Discussion of molecular imaging principles for the CXCR4/CXCL12 axis.

Main Results:

• [68Ga]Pentixafor enables non-invasive imaging of CXCR4 expression in vivo.
• [177Lu]/[90Y]Pentixather has shown promise in treating hematological neoplasms.
• CXCR4-directed imaging aids in understanding tumor heterogeneity and immune cell dynamics.

Conclusions:

• CXCR4-targeted PET imaging provides valuable insights into cancer biology and immune processes.
• Theranostic approaches using CXCR4 antagonists offer personalized treatment strategies.
• Molecular imaging of the CXCR4/CXCL12 axis is crucial for advancing oncology and immunology research.